All-trans retinoic acid (DrugBank: Retinoic acid)
1 disease告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
94 | 原発性硬化性胆管炎 | 2 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03359174 (ClinicalTrials.gov) | May 29, 2018 | 27/11/2017 | An Efficacy Trial of Low Dose All-trans Retinoic Acid in Patients With Primary Sclerosing Cholangitis | An Efficacy Trial of Low Dose All-trans Retinoic Acid (ATRA) in Patients With Primary Sclerosing Cholangitis | Cholangitis, Sclerosing | Drug: All-trans retinoic acid | Yale University | NULL | Recruiting | 18 Years | 80 Years | All | 20 | Phase 2 | United States |
2 | NCT01456468 (ClinicalTrials.gov) | October 2011 | 14/10/2011 | Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis | Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis - A Human Pilot Study | Cholangitis, Sclerosing | Drug: Oral all-trans retinoic acid (ATRA) | Yale University | Mayo Clinic | Completed | 18 Years | 80 Years | Both | 19 | Phase 1 | United States |